Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_
The market for therapeutics addressing castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) has shown significant growth in recent years. It is forecast to increase from $8.43 billion in 2025 to $8.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion has been influenced by factors such as the widespread occurrence of prostate cancer, the emergence of resistance to hormone therapy, breakthroughs in oncology drug development, the provision of hospital-based cancer treatment, and the growing demographic of aging males._x000D_
_x000D_
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is projected to demonstrate significant growth over the next few years. It is expected to reach $11.04 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. The expansion foreseen during the forecast period can be attributed to factors such as biomarker-driven treatment, advanced targeted therapies, the adoption of oral oncology, the expansion of the oncology pipeline, and personalized cancer care. Significant trends anticipated in this period involve the increasing utilization of androgen receptor inhibitors, the development of PARP inhibitor therapies, the broadening of combination treatment regimens, a greater emphasis on precision oncology, and a shift towards oral oncology drugs._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Industry Drivers: What’s Behind The Revenue Growth?#_x000D_
The increasing incidence of prostate cancer is projected to propel the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is defined as a malignant condition that develops within the prostate gland, a small organ found in men, positioned below the bladder and anterior to the rectum. This growing prevalence of prostate cancer is primarily attributed to the aging demographic, given that the risk of developing the disease significantly increases with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are instrumental in treating prostate cancer by targeting its advanced stages that no longer respond to conventional hormone therapy. These treatments enhance patient outcomes by slowing disease progression and managing associated symptoms, thereby improving their quality of life. As an illustration, in October 2025, NHS Digital, a UK-based government agency responsible for healthcare data and statistics, reported 58,137 new diagnoses of prostate cancer in England in 2023, which represented a 6 percent increase compared with 2022. Thus, the rising occurrence of prostate cancer is fundamentally driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market._x000D_
_x000D_
#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmentation: How Does The Market Break Down By Category?#_x000D_
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented – _x000D_
_x000D_
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy_x000D_
2) By Route Of Administration: Oral, Injectable, Intravenous_x000D_
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists_x000D_
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies_x000D_
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines_x000D_
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors_x000D_
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals_x000D_
_x000D_
#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Trends: What’s Shaping The Future Outlook?_x000D_
Within the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market, leading companies are concentrating on developing novel products and securing approvals, such as for dual-action tablets, to enhance treatment efficacy and patient outcomes. Dual-action tablets represent advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. Illustratively, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Akeega, a new tablet created for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically aimed at patients with BRCA mutations. When administered alongside prednisone, it markedly improves radiographic progression-free survival (rPFS) in comparison to conventional hormonal therapy alone._x000D_
_x000D_
#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Overview And Top Companies#_x000D_
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc. _x000D_
_x000D_
#View The Full Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:#_x000D_
_x000D_
#Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Geographic Analysis: Where Is Demand Accelerating Fastest?#_x000D_
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model